Russell Investments Group Ltd. cut its position in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 15.1% during the 3rd quarter, Holdings Channel reports. The firm owned 136,270 shares of the medical research company’s stock after selling 24,168 shares during the period. Russell Investments Group Ltd.’s holdings in IQVIA were worth $36,641,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently modified their holdings of IQV. Eurizon Capital SGR S.p.A. increased its position in shares of IQVIA by 11.4% in the third quarter. Eurizon Capital SGR S.p.A. now owns 54,052 shares of the medical research company’s stock worth $14,533,000 after acquiring an additional 5,527 shares in the last quarter. Maryland State Retirement & Pension System boosted its stake in shares of IQVIA by 14.1% during the 3rd quarter. Maryland State Retirement & Pension System now owns 9,933 shares of the medical research company’s stock valued at $2,670,000 after buying an additional 1,227 shares during the period. Ritholtz Wealth Management purchased a new position in shares of IQVIA during the 3rd quarter valued at $301,000. Walter Public Investments Inc. increased its stake in shares of IQVIA by 6.9% in the third quarter. Walter Public Investments Inc. now owns 14,491 shares of the medical research company’s stock worth $3,896,000 after acquiring an additional 931 shares during the last quarter. Finally, First Command Advisory Services Inc. increased its stake in shares of IQVIA by 225.8% in the third quarter. First Command Advisory Services Inc. now owns 1,375 shares of the medical research company’s stock worth $370,000 after acquiring an additional 953 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.
IQVIA Stock Performance
IQVIA stock opened at $265.14 on Tuesday. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $284.50. The stock has a 50-day simple moving average of $267.51 and a 200 day simple moving average of $212.00. The stock has a market capitalization of $43.70 billion, a price-to-earnings ratio of 32.22, a P/E/G ratio of 2.41 and a beta of 1.16. The company has a quick ratio of 0.83, a current ratio of 0.83 and a debt-to-equity ratio of 2.18.
Insider Buying and Selling
In other IQVIA news, insider Eric Sherbet sold 4,446 shares of the business’s stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $278.83, for a total value of $1,239,678.18. Following the completion of the transaction, the insider directly owned 24,989 shares of the company’s stock, valued at approximately $6,967,682.87. The trade was a 15.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider James G. Berkshire sold 2,668 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total value of $697,228.44. Following the completion of the transaction, the insider owned 10,890 shares of the company’s stock, valued at $2,845,883.70. This represents a 19.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 1.70% of the company’s stock.
Wall Street Analysts Forecast Growth
IQV has been the subject of a number of recent research reports. Royal Bank Of Canada raised their price target on IQVIA from $247.00 to $319.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 29th. Morgan Stanley upped their price target on IQVIA from $240.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Thursday, September 17th. Truist Financial raised their target price on shares of IQVIA from $329.00 to $346.00 and gave the company a “buy” rating in a research note on Wednesday, October 28th. Weiss Ratings lowered IQVIA from a “hold (c+)” rating to a “sell (d+)” rating in a report on Wednesday, October 28th. Finally, BMO Capital Markets increased their target price on shares of IQVIA from $270.00 to $305.00 in a research note on Monday, October 19th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and a consensus target price of $294.21.
Get Our Latest Stock Report on IQV
IQVIA Company Profile
IQVIA Holdings Inc. provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products. The company’s offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations.
Featured Articles
- Five stocks we like better than IQVIA
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
